ImmunoGen Message Board - Msg: 32507756

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunoGen

IMGN 31.23

0.0%

Feb 26 3:00 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Gary Mohilner who wrote (5638)	1/17/2020 10:50:25 AM
From: Wildbiftek	Read Replies (1) of 5665

I agree that the prospects are good and I've placed an appropriately sized bet in the stock as a result. However, there is definitely the possibility the trial fails for any number of reasons, competition emerges for the same target, or the FDA decides to move the bar for approval in this indication even after a SORAYA success. I believe Enyedy when he says that he is receiving plenty of "active inbound interest" but the terms may not be especially attractive as industry momentum still remains behind immune checkpoint and related assets rather than ADCs. This may change this year after 2 approvals late last year and if ZYME results are good.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next